How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

275 results for

Covid-19 and chloroquine

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Novel Coronavirus Infection (COVID‐19) in Children Younger Than One Year: A Systematic Review of Symptoms, Management and Outcomes Full Text available with Trip Pro

Novel Coronavirus Infection (COVID19) in Children Younger Than One Year: A Systematic Review of Symptoms, Management and Outcomes Novel coronavirus infection (COVID19) in children younger than one year: A systematic review of symptoms, management and outcomes - Raba - 2020 - Acta Paediatrica - Wiley Online Library Working off-campus? Learn about our By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term REVIEW ARTICLE (...) Free Access Novel coronavirus infection (COVID19) in children younger than one year: A systematic review of symptoms, management and outcomes Corresponding Author School of Medicine and Medical Sciences, University College Dublin (UCD), Dublin, Ireland Department of Paediatrics, Coombe Women and Infants University Hospital, Dublin, Ireland Correspondence Ali Ahmed Raba, Coombe Women and Infants University Hospital, Dublin 8, Dublin, Ireland. Email: Spire Fylde Coast Hospital, Blackpool, UK School

2020 Acta paediatrica

2. Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials Full Text available with Trip Pro

Both COVID-19 patients with pneumonia and onset time <=12 days Viral nucleic acid test 1, 2, 5, 6 ChiCTR2000029868 Hydroxychloroquine 4 Parallel 30–65 years Both COVID-19 patients with pneumonia The time when the nucleic acid of the novel coronavirus turns negative, T cell recovery time NA ChiCTR2000029559 Chloroquine phosphate 4 Parallel 18–70 years Both Severe patients with respiratory distress, RR >=30 times/min; in resting state, oxygen saturation <=93%; PaO2/FiO2 <=300 mmHg Time to clinical (...) Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials Cureus | Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials Journal Back Journal Specialties Back Specialties Publishing Back Publishing Channels Back Channels Academic Departments Back Academic Departments Professional Societies Back Professional Societies Competitions Back Competitions Current

2020 Cureus

3. Chloroquine phosphate for novel coronavirus (COVID-19) pneumonia : a systematic review and meta-analysis of randomised controlled trials

Chloroquine phosphate for novel coronavirus (COVID-19) pneumonia : a systematic review and meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2020 PROSPERO

4. Chloroquine combined with azithromycin for novel coronavirus (COVID-19) pneumonia: a systematic review and meta-analysis of randomised controlled trials

Chloroquine combined with azithromycin for novel coronavirus (COVID-19) pneumonia: a systematic review and meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

5. Chloroquine and hydroxychloroquine: Current evidence for their effectiveness in treating COVID-19

Chloroquine and hydroxychloroquine: Current evidence for their effectiveness in treating COVID-19 Chloroquine and hydroxychloroquine: Current evidence for their effectiveness in treating COVID-19 - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Chloroquine and hydroxychloroquine: Current evidence for their effectiveness in treating COVID-19 March 25, 2020 KERSTIN FRIE and KOME GBINIGIE Oxford COVID-19 (...) incorporated the usage of chloroquine/hydroxychloroquine for certain patients with COVID-19. Further research should address the optimal dose and duration of treatment, and explore side effects and long-term outcomes. There is a higher risk of side effects in the presence of renal and liver impairment, and there have been isolated reports of COVID-19 disease-causing renal and hepatic injury. Over twenty in vivo clinical trials have already been registered to test the use of chloroquine

2020 Oxford COVID-19 Evidence Service

6. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries Redirecting

2020 Covid-19 Ad hoc papers

7. Chloroquine and COVID-19 in children Full Text available with Trip Pro

Chloroquine and COVID-19 in children Chloroquine and COVID-19 in children | Canadian Paediatric Society A home for paediatricians. A voice for children and youth. Current: Chloroquine and COVID-19 in children Chloroquine and COVID-19 in children Posted on Mar 27 2020 by the Canadian Paediatric Society | Topic(s): , By Dr. Michael J. Rieder, Dr. Geert ‘t Jong, Dr. Nicole Le Saux Drug Therapy & Harardous Substances Committee; Infectious Diseases and Immunization Committee Canadian Paediatric (...) Society The COVID-19 pandemic has generated considerable interest in possible therapies, both prophylactic and acute. One potential therapy is the use of antimalarial drugs such as chloroquine or hydroxychloroquine. Laboratory studies have shown that chloroquine can reduce viral replication in vitro, but animal studies have not supported this finding. Several small studies in humans show conflicting results and the single, small controlled trial done to date using hydroxychloroquine [1] has not shown

2020 Canadian Paediatric Society

8. Hydroxychloroquine or Chloroquine for treating COVID-19 – a PROTOCOL for a systematic review of IPD

Hydroxychloroquine or Chloroquine for treating COVID-19 – a PROTOCOL for a systematic review of IPD Hydroxychloroquine or Chloroquine for treating COVID-19 – a PROTOCOL for a systematic review of IPD - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Hydroxychloroquine or Chloroquine for treating COVID-19 – a PROTOCOL for a systematic review of IPD April 14, 2020 Hydroxychloroquine or Chloroquine (...) worldwide. Another two publications have since shown equivocal findings (2,3). All the trials have serious methodological limitations and do not permit recommendations on the use of hydroxychloroquine/cholorquine in COVID-19. Known serious adverse effects associated with hydroxychloroquine/cholorquine administration also need to be considered. OBJECTIVE: To assess the benefits and harms of chloroquine or hydroxychloroquine for the treatment of COVID-19 infection. METHODS: A systematic review

2020 Oxford COVID-19 Evidence Service

9. COVID-19 Clinical Trials Report Card: Chloroquine and Hydroxychloroquine

COVID-19 Clinical Trials Report Card: Chloroquine and Hydroxychloroquine COVID-19 Clinical Trials Report Card: Chloroquine and Hydroxychloroquine - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website COVID-19 Clinical Trials Report Card: Chloroquine and Hydroxychloroquine May 11, 2020 Nicholas J. DeVito, Michael Liu, Jeffrey K Aronson On behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence (...) and Hydroxychloroquine Trials Chloroquine and/or hydroxychloroquine were mentioned in 218 studies. This represented 12% of all unique studies of COVID-19 in the ICTRP dataset. Of those, 158 (72%) were examining CQ/HCQ as active investigational treatments. The 60 trials in which either CQ or HCQ was being used as a control probably understates the true number, as many trials that plan to control with a “standard of care” are probably using CQ/HCQ. For example, in Iran it appears that use of hydroxychloroquine

2020 Oxford COVID-19 Evidence Service

10. Covid-19: More about chloroquine and hydroxychloroquine

Covid-19: More about chloroquine and hydroxychloroquine More about chloroquine and hydroxychloroquine - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website More about chloroquine and hydroxychloroquine May 30, 2020 Jeffrey K Aronson, Robin E Ferner* On behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences University (...) of Oxford *University of Birmingham Correspondence to VERDICT The hypothesis that the 4-aminoquinolines chloroquine and hydroxychloroquine may be beneficial in the treatment of COVID-19 is a weak one, based on poor mechanistic reasoning and inconsistent results of studies in vitro, in laboratory animals, and in humans. It is likely that even if chloroquine and hydroxychloroquine are effective in COVID-19, the beneficial effects will be small. The risks of adverse reactions to these drugs may

2020 Oxford COVID-19 Evidence Service

11. Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of novel coronavirus pneumonia 2019

Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of novel coronavirus pneumonia 2019 Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

12. Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians Full Text available with Trip Pro

Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians | Annals of Internal Medicine LOGIN TO YOUR ACCOUNT or Create a new (...) of coronavirus disease 2019 (COVID-19) ( ), using an updated evidence review conducted on 8 May 2020 ( ). The evidence update identified 6 new studies: 4 observational studies ( ) addressed use of hydroxychloroquine alone, 1 observational study ( ) focused on hydroxychloroquine alone and in combination with azithromycin, and 1 observational study ( ) assessed use of chloroquine alone (previously, no studies were available on the use of chloroquine alone). All new studies evaluated use of the pharmacologic

2020 American College of Physicians

13. Treating COVID-19 with chloroquine Full Text available with Trip Pro

Treating COVID-19 with chloroquine Treating COVID-19 with chloroquine — CDEI Open Menu Close Menu Open Menu Close Menu May 17 Written By Citation: Huang, M., Tang, T., Pang, P., Li, M., Ma, R., Lu, J., ... & Hong, Z. (2020). Treating COVID-19 with chloroquine. Journal of molecular cell biology . DOI: Full PICO and Limitations in text: Population: 22 adult patients (≥18 years) who had been diagnosed with COVID-19 as confirmed by a positive test for SARS-CoV-2 by RT-PCR assay before enrollment (...) adverse events. Limitations: Study design: Small scale study (n=22) Unclear if any blinding occurred in study. Randomization process of patients unclear. Standard of care is not defined Outcome data: Unclear if data is significant, no p-value provided Abbreviations ALT = alanine aminotransferase AST = aspartate aminotransferase BID = twice daily CI = confidence interval Cr = creatinine CrCl = creatinine clearance CRP = C-reactive protein COVID-19 = coronavirus disease ECMO = extracorporeal membrane

2020 Covid-19 Drug Evidence Initiative

14. Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study Full Text available with Trip Pro

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study CDEI - Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19 — CDEI Open Menu Close Menu Open Menu Close Menu Jun 26 Written By Note: Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should (...) not be reported in news media as established information (medRxiv). Citation: Chen, L. , Zhang, Z., Fu, J., Feng, Z., Zhang, S., ... Yin, Z. (2020). Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study. medRxiv. DOI: Full PICO and Limitations in text: Population: 48 patients aged 18 to 75 years with moderate COVID-19, diagnosed by positive RT-PCR or with CT scan of the chest for lung changes characteristic of COVID-19

2020 Covid-19 Drug Evidence Initiative

15. Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Full Text available with Trip Pro

Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians | Annals of Internal Medicine LOGIN TO YOUR ACCOUNT or Create a new account Email Can't sign in? Forgot your (...) practice points on the use of chloroquine or hydroxychloroquine alone or in combination with azithromycin for the prophylaxis or treatment of coronavirus disease 2019 (COVID-19) ( , ) from the living status. This decision was made in light of recent information on the topic. Three large, in-progress randomized controlled trials (RCTs) with strong study designs ceased enrollment for the hydroxychloroquine-only versus control comparison early due to lack of efficacy in preliminary analyses

2020 American College of Physicians

16. An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario Full Text available with Trip Pro

, Karnataka, India Search for other articles: DOI: | Published online: 14 Sep 2020 Access Metrics All Time Past Year Past 30 Days Full Text 685 685 291 PDF 250 250 78 Abstract A novel coronavirus infection coronavirus disease 2019 (COVID-19) emerged from Wuhan, Hubei Province of China, in December 2019 caused by SARS-CoV-2 is believed to be originated from bats in the local wet markets. Later, animal to human and human-to-human transmission of the virus began and resulting in widespread respiratory (...) vaccines, peptides, nucleic acids, plant-derived, recombinant vaccines are under pipeline. This article concludes and highlights ongoing advances in drug repurposing, therapeutics and vaccines to counter COVID-19, which collectively could enable efforts to halt the pandemic virus infection. Keywords: ; ; ; Introduction In December 2019, a novel coronavirus (CoV) infection emerged from Wuhan, Hubei Province of China, has spread to many countries worldwide [ ], [ ]. It is believed to be originated from

2020 Journal of Basic and Clinical Physiology and Pharmacology

17. Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) : 10.3389/fmed.2020.00482. eCollection 2020. Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis , , , , , Affiliations Expand Affiliations 1 Department of Pediatrics, AIIMS Bhubaneswar, Bhubaneswar, India. 2 Evidence Based Health Informatics Unit, Department of Telemedicine, PGIMER, Chandigarh, India. 3 Department of Medicine, VMMC, Safdarjung Hospital, New Delhi, India. 4 Department of Microbiology

2020 EvidenceUpdates

18. A Systematic Review on the Potency and How Safe Chloroquine is for the Treatment of COVID-19 Full Text available with Trip Pro

: SARS-CoV-2, COVID-19, Chloroquine, Pneumonia, Coronavirus Downloads Download data is not yet available. References Colson, P., Rolain, J.M., and Raoult, D. (2020). Chloroquine for the 2019 novel coronavirus SARSCoV-2. Int J. Antimicrob Agents. 13:105-123. Farner, K. (2020). Chloroquine use as a Global Challenge. Italian Society of Infectious and Tropical disease. 2:23-26. Gao, J., Tian, Z., and Yang, X. (2020). Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 (...) , C., Zhu, F., Liu, X., and Zhang, J. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama. 1:15-18. Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., and Xu, M. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2:8-12. Wu, Z., and McGoogan, J.M. (2020). Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak

2020 AIJR Publisher

19. Chloroquine and Hydroxychloroquine for the treatment of COVID-19: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Chloroquine and Hydroxychloroquine for the treatment of COVID-19: A Systematic Review and Meta-analysis Chloroquine and Hydroxychloroquine for the treatment of COVID-19: A Systematic Review and Meta-analysis | medRxiv Search for this keyword Chloroquine and Hydroxychloroquine for the treatment of COVID-19: A Systematic Review and Meta-analysis Arunmozhimaran Elavarasi , Manya Prasad , Tulika Seth , Ranjit Kumar Sahoo , Karan Madan , Neeraj Nischal , Manish Soneja , Atul Sharma , Subir Kumar (...) ) and chloroquine (CQ) have been used for its treatment but their safety and efficacy remain uncertain. Objective We performed a systematic review to synthesize the available data on the efficacy and safety of CQ and HCQ for the treatment of COVID-19. Methods Two reviewers searched for published and pre-published relevant articles between December 2019 to 8th June 2020. The data from the selected studies were abstracted and analyzed for efficacy and safety outcomes. Critical appraisal of the evidence was done

2020 Cold Spring Harbor Laboratory

20. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials Full Text available with Trip Pro

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials | medRxiv Search for this keyword Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials Cathrine Axfors , Andreas M. Schmitt , Perrine (...) /chloroquine, which currently face recruitment challenges or early discontinuation. We aimed to estimate the effects of hydroxychloroquine and chloroquine on survival in COVID-19 from all currently available RCT evidence, published and unpublished. We conducted a rapid meta-analysis of ongoing, completed, or discontinued RCTs on hydroxychloroquine or chloroquine treatment for any COVID-19 patients (protocol: ). We systematically identified unpublished RCTs (ClinicalTrials.gov, WHO International Clinical

2020 Cold Spring Harbor Laboratory

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>